Teriflunomide May Delay Onset of MS Symptoms in People With RIS
A recent Phase 3 trial showed people with radiologically isolated syndrome (RIS) who took Aubagio were 72 percent less likely to later develop MS symptoms.
Source: everydayhealth.com
Stay updated with breaking news from Scott Otallah. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A recent Phase 3 trial showed people with radiologically isolated syndrome (RIS) who took Aubagio were 72 percent less likely to later develop MS symptoms.
View the Winston-Salem Journal for Monday, October 11, 2021
Wake Forest medical school joins national youth concussion study